Their primary therapeutic actions include stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying to promote satiety, and acting on hypothalamic appetite centers to reduce hunger and caloric intake
For the secondary outcomes, the hazard ratios were below the null value for myocardial infarction, ischaemic stroke, cardiovascular mortality, heart failure, and all cause mortality, but with wide confidence intervals that included the null
And you do not have to abandon your recovery, your values, or your peace with food simply because you cannotor do not want tokeep pace with everyone else
However, like most therapies targeting metabolic pathways, they are not free of risks
June 20, 2024.